Karyotype and DNA-Methylation Responses in Myelodysplastic Syndromes following Treatment with Traditional Chinese Formula Containing Arsenic

Table 1

General information of patients.

Patient	Sex	Age	Diagnosis	Karyotype		Blood arsenic concentration (ug/L)	IPSS	Clinical evaluation
				Before	After
1*	F	31	MDS-RCMD	47,XY,+8[10]	47,XY,+8[10]	7.60	Mid-risk I	Improve
2*	F	41	MDS-RCMD	46,XX,+8,−5[5]/47,XX,+8[15]	46,XX,+8,−5[15]/46,XX[1]	35.39	Mid-risk I	Improve
3*	M	31	MDS-RCMD	46,XY[20]	46,XY[20]	10.56	Mid-risk I	Improve
4*	M	23	MDS-RCMD	47,XY,+8[8]/46,XY[10]	47,XY,+8[11]/46,XY[9]	31.76	Mid-risk I	Improve
5*	M	41	MDS-RCMD	46,XY[20]	46,XY[20]	20.44	Mid-risk I	Improve
6*	F	25	MDS-RCMD	46,XX[20]	47,XX,+8[6],−X[2]/46,XX[23]	19.74	Mid-risk I	Improve
7*	M	26	MDS-RCMD	46,XY[20]	46,XY[20]		Mid-risk I	Improve
8*	M	34	MDS-RCMD	46,XY[20]	46,XY[20]		Mid-risk I	Improve
9*	M	48	MDS-RCMD	46,XY[20]	46,XY[20]		Mid-risk I	CR
10*	M	33	MDS-RCMD	46,XY[20]	46,XY[20]		Mid-risk I	Improve
11*	M	40	MDS-RCMD	46,XY[20]	46,XY[20]		Mid-risk I	Improve
12*	M	28	MDS-RCMD	46,XY[24]	46,XY[20]	11.42	Mid-risk I	Improve
13*	F	21	MDS-RCMD	46,XX[20]	46,XX[20]	18.34	Mid-risk I	CR
14*	F	57	MDS-RAEB I	45-46,−X/Xq-[10]	45-46-C/cq-(7?,9?,x?)[10]/46,xx[1]		Mid-risk II	Improve
15	F	31	MDS-RCMD	46,XX[16]			Mid-risk I
16	F	57	MDS-RCMD	46,XX[20]			Mid-risk I
17	F	25	MDS-RCMD	46,XX[8]			Mid-risk I
18	M	40	MDS-RCMD-RS	47,XY,+8[6]/46,XY[1]			Mid-risk I
19	M	43	MDS-RCMD	47,XY,+8[9]/46,XY[11]			Mid-risk I
20	M	69	MDS-RCMD	45,XY, −7[16]/46,XY[3]			Mid-risk II
21	F	36	MDS-RAEB I	46,XX,4p-[19]/46,XX[1]			Mid-risk II
22	M	51	MDS-RCMD	48,XY,9q-,+10,+14[4]/9q-,+14[8]			Mid-risk II
23	F	54	MDS-RCMD	47,XX,+9[16]			Mid-risk II
24	M	34	MDS-RCMD	46,XY,dup(1q)[20]			Mid-risk II
25	F	75	MDS-RCMD	45,XX, −7[13]			Mid-risk II

*Gene methylation and karyotype were analyzed before and after treatment.